summary: This study investigates the incidence of similar antibodies to those described above, this time in association with the new generation drug Natalizumab. In a large cohort taken from 2 randomized control studies, 6% of patients developed antibodies. Therefore the presence of antibodies should be investigated in patients who respond poorly to the drug.

authors: Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

source: Neurology. 2007 Oct 2;69(14):1391-403. Epub 2007 Aug 29

weblink: click here

related research news: click here

glossary: